Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Amy H, Kao"'
Autor:
John E. McKinnon, Joel Santiaguel, Claudia Murta de Oliveira, Dongzi Yu, Mukhy Khursheed, Flavie Moreau, Lena Klopp‐Schulze, Jamie Shaw, Sanjeev Roy, Amy H. Kao, the ANEMONE Study Team
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 12, Pp 2640-2653 (2023)
Abstract Enpatoran is a selective inhibitor of toll‐like receptors 7 and 8 (TLR7/8) that potentially targets pro‐inflammatory pathways induced by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A phase II study conducted in Braz
Externí odkaz:
https://doaj.org/article/dac7d19bf3f140e78fae2fdc00bbf872
Autor:
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 1, Pp 38-48 (2023)
Objective Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of
Externí odkaz:
https://doaj.org/article/fbfb7923863e4170999f2062f9b263dc
Autor:
Kenneth Kalunian, Susan Manzi, Amy H Kao, Eric F Morand, Brad H Rovin, Karen H Costenbader, Karin Tse, Laura Eve Schanberg, Yaritza Peña, Kathleen Arntsen, Kenneth Getz, Joan M Von Feldt, Erin Connolly-Strong, Sanjyot Sangodkar, Lauren Bloch, Bradley Dickerson, Sydney Evans, Sandra C Raymond, Angel Williams Derricott, David Zook, Timothy Franson, Leslie M Hanrahan
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss 1 (2021)
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritise and address top barriers in lupus impacting diagnosis, care, treatment and research. To conduct this process, the ALPHA Project c
Externí odkaz:
https://doaj.org/article/5818f0eec0ce4fc69c7eeb81a3be9cc1
Autor:
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
Publikováno v:
ACR Open Rheumatology. 5:38-48
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b9466da0aa9a79b3ec812df5812e5ab
https://doi.org/10.1002/acr2.11511
https://doi.org/10.1002/acr2.11511
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/53211577c68242d08527bf89d4a18f2a
Autor:
Daniel J, Wallace, Thomas, Dörner, David S, Pisetsky, Jorge, Sanchez-Guerrero, Anand C, Patel, Dana, Parsons-Rich, Claire, Le Bolay, Elise E, Drouin, Amy H, Kao, Hans, Guehring, Maria, Dall'Era
Publikováno v:
ACR open rheumatologyREFERENCES.
Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the efficacy and safety of evobrutinib in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8c914e887bef8a0fc2d37ee1efc59306
https://pubmed.ncbi.nlm.nih.gov/36530019
https://pubmed.ncbi.nlm.nih.gov/36530019
Autor:
Eric F Morand, David A. Isenberg, Joan T. Merrill, Cristina Vazquez-Mateo, P Chang, Amy H. Kao, Daniel J. Wallace, Kishore Pudota, Cynthia Aranow
Publikováno v:
Rheumatology (Oxford, England)
Objective Low disease activity (LDA) and remission are emerging treat-to-target (T2T) endpoints in SLE. However, the rates at which these endpoints are met in patients with high disease activity (HDA) are unknown. Atacicept, which targets B lymphocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393407b3dc87a11efe13b88698c5b23d
http://europepmc.org/articles/PMC7516108
http://europepmc.org/articles/PMC7516108
Autor:
Julie Bonin, Eric F Morand, Oliver Gunther, Ying Sun, Amy H. Kao, Rachel Koelmeyer, Hieu T. Nim, Alberta Hoi
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-9 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy
BackgroundWe sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318c3624bf465bb7afd218a5881eb6e0
https://doi.org/10.1186/s13075-021-02572-1
https://doi.org/10.1186/s13075-021-02572-1
Autor:
Cecilia P. Chung, Joan M. Bathon, Sabahat Bokhari, Roger S. Blumenthal, Mary Chester M. Wasko, Afshin Zartoshti, C. Michael Stein, Jon T. Giles, Amy H. Kao, Moyses Szklo
Publikováno v:
Arthritis Rheumatol
OBJECTIVE Rheumatoid arthritis (RA) patients with the lowest circulating low-density lipoprotein (LDL) concentrations are at heightened risk of cardiovascular events. However, the atherosclerosis burden within this subgroup is unknown. METHODS RA pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8076686241a21bfc287cfde4ed3bed1e
https://doi.org/10.1002/art.40889
https://doi.org/10.1002/art.40889
Autor:
M. Ilyas Kamboh, Xingbin Wang, Amy H. Kao, Michael M. Barmada, Ann Clarke, Rosalind Ramsey-Goldman, Susan Manzi, F. Yesim Demirci
Publikováno v:
Autoimmune Diseases, Vol 2013 (2013)
Background. The persistent presence of antiphospholipid antibodies (APA) may lead to the development of primary or secondary antiphospholipid syndrome. Although the genetic basis of APA has been suggested, the identity of the underlying genes is larg
Externí odkaz:
https://doaj.org/article/eab8eb9e259b4ab6bc701f48344a90cc